Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Primary leiomyosarcoma of the skin: a comprehensive review on diagnosis and treatment

Abstract

Sarcomas are a heterogeneous group of mesenchymal tumors which can affect bone and soft tissue. Leiomyosarcoma (LMS) is a rare subtype localized to the skin or subcutaneous tissue. Due to the heterogeneity of sarcomas, reviews and guidelines with an in-depth focus specifically on primary LMS of the skin are sparse. This article is intended to provide an up to date and systematic overview on diagnosis, treatment, and surveillance of this rare entity to provide a framework for decision making and management for dermato-oncologists. We discuss novel treatment options for advanced disease such as targeted therapy with kinase inhibitors and immune checkpoint blockade which may improve the prognosis even in advanced stages of LMS.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. 1.

    Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol. 1997;24(5):504–14.

  2. 2.

    Stout AP, Hill WT. Leiomyosarcoma of the superficial soft tissues. Cancer. 1958;11(4):844–54.

  3. 3.

    Cook TF, Fosko SW. Unusual cutaneous malignancies. Semin Cutan Med Surg. 1998;17(2):114–32.

  4. 4.

    Holst VA, Junkins-Hopkins JM, Elenitsas R. Cutaneous smooth muscle neoplasms: Clinical features, histologic findings, and treatment options. J Am Acad Dermatol. 2002;46(4):477–90. quiz, 491 – 474.

  5. 5.

    Wascher RA, Lee MY. Recurrent cutaneous leiomyosarcoma. Cancer. 1992;70(2):490–2.

  6. 6.

    Kohlmeyer J, Steimle-Grauer SA, Hein R. Cutaneous sarcomas. J Dtsch Dermatol Ges. 2017;15(6):630–48.

  7. 7.

    Deneve JL, Messina JL, Bui MM, Marzban SS, Letson GD, Cheong D, et al. Cutaneous leiomyosarcoma: Treatment and outcomes with a standardized margin of resection. Cancer Control. 2013;20(4):307–12.

  8. 8.

    Fields JP, Helwig EB. Leiomyosarcoma of the skin and subcutaneous tissue. Cancer. 1981;47(1):156–69.

  9. 9.

    Phelan JT, Sherer W, Mesa P. Malignant smoothmuscle tumors (leiomyosarcomas) of soft-tissue origin. N Engl J Med. 1962;266:1027–30.

  10. 10.

    Dahl I, Angervall L. Cutaneous and subcutaneous leiomyosarcoma. A clinicopathologic study of 47 patients. Pathol Eur. 1974;9(4):307–15.

  11. 11.

    Jensen ML, Jensen OM, Michalski W, Nielsen OS, Keller J. Intradermal and subcutaneous leiomyosarcoma: A clinicopathological and immunohistochemical study of 41 cases. J Cutan Pathol. 1996;23(5):458–63.

  12. 12.

    Farran Y, Padilla O, Chambers K, Philipovskiy A, Nahleh Z. Atypical presentation of radiation-associated breast angiosarcoma: A case report and review of literature. Am J Case Rep. 2017;18:1347–50.

  13. 13.

    Sabater-Marco V, Ferrando-Roca F, Morera-Faet A, Garcia-Garcia JA, Bosch SB, Lopez-Guerrero JA. Primary cutaneous leiomyosarcoma arising in a patient with li-fraumeni syndrome: A neoplasm with unusual histopathologic features and loss of heterozygosity at tp53 gene. Am J Dermatopathol. 2018;40(3):225–7.

  14. 14.

    Gao P, Seebacher NA, Hornicek F, Guo Z, Duan Z. Advances in sarcoma gene mutations and therapeutic targets. Cancer Treat Rev. 2018;62:98–109.

  15. 15.

    Aneiros-Fernandez J, Antonio Retamero J, Husein-Elahmed H, Ovalle F, Aneiros-Cachaza J. Primary cutaneous and subcutaneous leiomyosarcomas: Evolution and prognostic factors. Eur J Dermatol. 2016;26(1):9–12.

  16. 16.

    Patt JC, Haines N. Soft tissue sarcomas in skin: Presentations and management. Semin Oncol. 2016;43(3):413–8.

  17. 17.

    Corcoran S, Hogan AM, Nemeth T, Bennani F, Sullivan FJ, Khan W, et al. Isolated cutaneous metastasis of uterine leiomyosarcoma: Case report and review of literature. Diagn Pathol. 2012;7:85.

  18. 18.

    Zarcone N, Ciacci A, Di Gregorio C, Rivasi F. [subcutaneous metastasis of uterine leiomyosarcoma]. Minerva Ginecol. 1988;40(8):489–91.

  19. 19.

    Vandergriff T, Krathen RA, Orengo I. Cutaneous metastasis of leiomyosarcoma. Dermatol Surg. 2007;33(5):634–7.

  20. 20.

    Soipi S, Vucic M, Ulamec M, Tomas D, Kruslin B, Spajic B. Leiomyosarcoma of the spermatic cord with scalp metastasis: Case report and literature review. Coll Antropol. 2014;38(2):763–6.

  21. 21.

    Alessi E, Innocenti M, Sala F. Leiomyosarcoma metastatic to the back and scalp from a primary neoplasm in the uterus. Am J Dermatopathol. 1985;7(5):471–6.

  22. 22.

    Annest NM, Grekin SJ, Stone MS, Messingham MJ. Cutaneous leiomyosarcoma: A tumor of the head and neck. Dermatol Surg. 2007;33(5):628–33.

  23. 23.

    Bernstein SC, Roenigk RK. Leiomyosarcoma of the skin. Treatment of 34 cases. Dermatol Surg. 1996;22(7):631–5.

  24. 24.

    Banuls J, Botella R, Sevila A, Aranda I, Roman P. Leiomyosarcoma of the upper lip. Int J Dermatol. 1994;33(1):48–9.

  25. 25.

    Piana M, Martinez Mansur R, Codone J, Elizalde F, Diez M, Reyes E, et al. [penile leiomyosarcoma: Case report and bibliographic review]. Arch Esp Urol. 2006;59(7):728–31.

  26. 26.

    Pow-Sang MR, Orihuela E. Leiomyosarcoma of the penis. J Urol. 1994;151(6):1643–5.

  27. 27.

    Rabinovich J. Leiomyosarcoma of the foreskin: A rare case of mesenchymal foreskin tumor. Urologe A. 2018;57(5):591–3.

  28. 28.

    John T, Portenier D, Auster B, Mehregan D, Drelichman A, Telmos A. (2006). Leiomyosarcoma of scrotum–case report and review of literature. Urology. 67(2):424 e413–424 e415.

  29. 29.

    Lo Muzio L, Favia G, Farronato G, Piattelli A, Maiorano E. Primary gingival leiomyosarcoma. A clinicopathological study of 1 case with prolonged survival. J Clin Periodontol. 2002;29(2):182–7.

  30. 30.

    Kaltreider SA, Destro M, Lemke BN. Leiomyosarcoma of the orbit. A case report and review of the literature. Ophthalmic Plast Reconstr Surg. 1987;3(1):35–41.

  31. 31.

    Murback NDN, Takita LC, Castro BC, Hans Filho G. Cutaneous leiomyosarcoma on the face. An Bras Dermatol. 2018;93(2):262–4.

  32. 32.

    Kim NG, Kim JO, Park YJ, Kim JS, Lee YJ, Lee KS. Cutaneous leiomyosarcoma of the face. Arch Craniofac Surg. 2017;18(2):145–8.

  33. 33.

    Lonsdale RN, Widdison A. Leiomyosarcoma of the nipple. Histopathology. 1992;20(6):537–9.

  34. 34.

    Alessi E, Sala F. Leiomyosarcoma in ectopic areola. Am J Dermatopathol. 1992;14(2):165–9.

  35. 35.

    Hashimoto H, Daimaru Y, Tsuneyoshi M, Enjoji M. Leiomyosarcoma of the external soft tissues. A clinicopathologic, immunohistochemical, and electron microscopic study. Cancer. 1986;57(10):2077–88.

  36. 36.

    Winchester DS, Hocker TL, Brewer JD, Baum CL, Hochwalt PC, Arpey CJ, et al. Leiomyosarcoma of the skin: Clinical, histopathologic, and prognostic factors that influence outcomes. J Am Acad Dermatol. 2014;71(5):919–25.

  37. 37.

    Sleiwah A, Clinton A, Herbert K. (2018). Delayed diagnosis of dermal leiomyosarcoma mimicking keloid scar. BMJ Case Rep. 2018;https://doi.org/10.1136/bcr-2017-222616.

  38. 38.

    Lin JY, Tsai RY. Subcutaneous leiomyosarcoma on the face. Dermatol Surg. 1999;25(6):489–91.

  39. 39.

    Massi D, Franchi A, Alos L, Cook M, Di Palma S, Enguita AB, et al. Primary cutaneous leiomyosarcoma: Clinicopathological analysis of 36 cases. Histopathology. 2010;56(2):251–62.

  40. 40.

    Luke JJ, Keohan ML. Advances in the systemic treatment of cutaneous sarcomas. Semin Oncol. 2012;39(2):173–83.

  41. 41.

    Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14(5):1679–89.

  42. 42.

    Harding-Jackson N, Sangueza M, Mackinnon A, Suster S, Plaza JA. Spindle cell atypical fibroxanthoma: Myofibroblastic differentiation represents a diagnostic pitfall in this variant of afx. Am J Dermatopathol. 2015;37(7):509–14. quiz 515 – 506.

  43. 43.

    Fernandez-Flores A, Monteagudo C. Immunoexpression of p53 in cutaneous and subcutaneous leiomyosarcomas. Ann Diagn Pathol. 2016;24:25–9.

  44. 44.

    Idriss MH, Elston DM. S100a6 expression in cutaneous smooth muscle neoplasms. APMIS. 2015;123(10):832–6.

  45. 45.

    Suster S, Rosen LB, Sanchez JL. Granular cell leiomyosarcoma of the skin. Am J Dermatopathol. 1988;10(3):234–9.

  46. 46.

    Suster S. Epithelioid leiomyosarcoma of the skin and subcutaneous tissue. Clinicopathologic, immunohistochemical, and ultrastructural study of five cases. Am J Surg Pathol. 1994;18(3):232–40.

  47. 47.

    Diaz-Cascajo C, Borghi S, Weyers W. Desmoplastic leiomyosarcoma of the skin. Am J Dermatopathol. 2000;22(3):251–5.

  48. 48.

    Kraft S, Fletcher CD. Atypical intradermal smooth muscle neoplasms: Clinicopathologic analysis of 84 cases and a reappraisal of cutaneous “leiomyosarcoma”. Am J Surg Pathol. 2011;35(4):599–607.

  49. 49.

    Coindre JM, Trojani M, Contesso G, David M, Rouesse J, Bui NB, et al. Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer. 1986;58(2):306–9.

  50. 50.

    Group ESESNW. Soft tissue and visceral sarcomas: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii102–112.

  51. 51.

    Roberge D, Hickeson M, Charest M, Turcotte RE. Initial mcgill experience with fluorodeoxyglucose pet/ct staging of soft-tissue sarcoma. Curr Oncol. 2010;17(6):18–22.

  52. 52.

    Roberge D, Vakilian S, Alabed YZ, Turcotte RE, Freeman CR, Hickeson M. Fdg pet/ct in initial staging of adult soft-tissue sarcoma. Sarcoma, 2012;https://doi.org/10.1155/2012/960194.

  53. 53.

    Tsutsumida A, Yoshida T, Yamamoto Y, Itoh T, Minakawa H, Sugihara T. Management of superficial leiomyosarcoma: A retrospective study of 10 cases. Plast Reconstr Surg. 2005;116(1):8–12.

  54. 54.

    Starling J IIIrd, & Coldiron BM. Mohs micrographic surgery for the treatment of cutaneous leiomyosarcoma. J Am Acad Dermatol. 2011;64(6):1119–22.

  55. 55.

    McKee MD, Liu DF, Brooks JJ, Gibbs JF, Driscoll DL, Kraybill WG. The prognostic significance of margin width for extremity and trunk sarcoma. J Surg Oncol. 2004;85(2):68–76.

  56. 56.

    Humphreys TR, Finkelstein DH, Lee JB. Superficial leiomyosarcoma treated with mohs micrographic surgery. Dermatol Surg. 2004;30(1):108–12.

  57. 57.

    Hollmig ST, Sachdev R, Cockerell CJ, Posten W, Chiang M, Kim J. Spindle cell neoplasms encountered in dermatologic surgery: A review. Dermatol Surg. 2012;38(6):825–50.

  58. 58.

    Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.

  59. 59.

    Mouridsen HT, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder JH, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase ii/phase iii study of the eortc soft tissue and bone sarcoma group. Eur J Cancer Clin Oncol. 1987;23(10):1477–83.

  60. 60.

    Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: An open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388(10043):488–97.

  61. 61.

    Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, et al. Phase ii study of et-743 in advanced soft tissue sarcomas: A european organisation for the research and treatment of cancer (eortc) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23(3):576–84.

  62. 62.

    Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, et al. Phase ii and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22(8):1480–90.

  63. 63.

    von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, Ryan CW, et al. Phase 2 southwest oncology group-directed intergroup trial (s0505) of sorafenib in advanced soft tissue sarcomas. Cancer. 2012;118(3):770–6.

  64. 64.

    D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (alliance a091401): Two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416–26.

  65. 65.

    D’Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, et al. Prevalence of tumor-infiltrating lymphocytes and pd-l1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46(3):357–65.

  66. 66.

    Maki RG, Jungbluth AA, Gnjatic S, Schwartz GK, D’Adamo DR, Keohan ML, et al.. A pilot study of anti-ctla4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma. 2013;https://doi.org/10.1155/2013/168145.

  67. 67.

    Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (sarc028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493–501.

  68. 68.

    Liao WC, Wang YC, Ma H. Cutaneous leiomyosarcoma: The clinical experience of taipei veterans general hospital revisited. Ann Plast Surg. 2017;78(3 Suppl 2):47-s51.

Download references

Author information

Correspondence to Carola Berking.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zacher, M., Heppt, M.V., Brinker, T.J. et al. Primary leiomyosarcoma of the skin: a comprehensive review on diagnosis and treatment. Med Oncol 35, 135 (2018). https://doi.org/10.1007/s12032-018-1196-2

Download citation

Keywords

  • Leiomyosarcoma
  • Soft tissue sarcoma
  • Skin
  • Platelet-derived growth factor
  • Immune checkpoint blockade